FDA Clearance Tracker · P040013-S024
GEM21S Growth Factor Enhanced Matrix
Last checked: Nov 20, 2026Latest source record: Dec 4, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Dec 4, 2020
Approved
Time to decision
231 days
Received Apr 17, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P040013-S024
- Device name
- GEM21S Growth Factor Enhanced Matrix
- Applicant
- Lynch Biologics, LLC
- Applicant location
- Franklin, TN
- Received
- Apr 17, 2020
- Decided
- Dec 4, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P040013
Device type
- Device class
- Class III
- Regulation
- 21 CFR 872.3930
- Specialty
- Dentistry & Oral Surgery
FDA's approval statement
As written in FDA's record.
Change in supplier for the formulation, filling, and testing (with the exception of the Bioassay) of the rhPDGF-BB syringe component of GEM21S Growth Factor Enhanced Matrix to a manufacturing site located at Pyramid Laboratories, Inc., 3598 Cadillac Ave., Costa Mesa, CA 92626.
Source documents
Other decisions for Lynch Biologics, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.